Base de dados : MEDLINE
Pesquisa : D06.472.334.851.687 [Categoria DeCS]
Referências encontradas : 3092 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 310 ir para página                         

  1 / 3092 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28700760
[Au] Autor:Lam Y; Coe C; Mounsey A
[Ad] Endereço:Department of Family Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
[Ti] Título:PURLs: Which combined OC to prescribe with CV safety in mind?
[So] Source:J Fam Pract;66(7):454-456, 2017 Jul.
[Is] ISSN:1533-7294
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:With various formulations available, which combined OC should you recommend to minimize not only the risk of PE, but also the risk of stroke and MI?
[Mh] Termos MeSH primário: Anticoncepcionais Orais Combinados/efeitos adversos
Prescrições de Medicamentos
Segurança do Paciente
Padrões de Prática Médica
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Infarto do Miocárdio/induzido quimicamente
Congêneres da Progesterona/efeitos adversos
Embolia Pulmonar/induzido quimicamente
Fatores de Risco
Acidente Vascular Cerebral/induzido quimicamente
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contraceptives, Oral, Combined); 0 (Progesterone Congeners)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170815
[Lr] Data última revisão:
170815
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170713
[St] Status:MEDLINE


  2 / 3092 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28346192
[Au] Autor:Deleruyelle LJ
[Ad] Endereço:Frances Payne Bolton School of Nursing at Case Western Reserve University. dr.laura63@hotmail.com.
[Ti] Título:Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 3.
[So] Source:Int J Pharm Compd;21(1):6-16, 2017 Jan-Feb.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The use of compounded bioidentical hormone replacement therapy by menopausal women has become a popular alternative to traditional synthetic conjugated equine estrogen and progestin hormone replacement therapy due to safety concerns raised by recent studies. However, due to the lack of randomized, large-scale trials to evaluate the efficacy and side-effect profile of compounded bioidentical hormone replacement therapy many healthcare providers are reluctant to prescribe such therapy. The purpose of this study was to compare women's menopausal symptom relief and side effects experienced when using compounded bioidentical hormone replacement therapy and traditional hormone replacement therapy. A descriptive comparative design was used. Inferential and descriptive statistical procedures including a paired difference t-test, two-sample t-test, and f-tests (percentage, mean, standard deviation, frequency) were run on the Statistical Package for the Social Sciences. The framework used to guide this study was Lenz and Pugh's Theory of Unpleasant Symptoms. Surveys were distributed once to a convenient sample of women aged 35 and older when they dropped off or picked up their prescriptions at a pharmacy. Of the 216 surveys distributed, 70 were returned from those women taking compounded bioidentical hormone replacement therapy and 53 from traditional hormone replacement therapy. The survey contained 15 questions pertaining to age, duration of hormone replacement therapy, type and formulation of hormone replacement therapy, reasons for initiating hormone replacement therapy, symptoms before and one month after hormone replacement therapy, and side effects related to hormone replacement therapy. Included in part 1 of this series of articles was the introduction to the study conducted and the results of the literature review that was conducted for the purpose of examining the current data related to the topic of hormone replacement therapy. Part 2 provided a brief discussion on the significance of this study to nursing and provided the methods used in this study. The results and conclusion of this study are provided within this article.
[Mh] Termos MeSH primário: Medicamentos Biossimilares/administração & dosagem
Terapia de Reposição de Estrogênios/métodos
Estrogênios Conjugados (USP)/administração & dosagem
Menopausa/efeitos dos fármacos
Congêneres da Progesterona/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Medicamentos Biossimilares/efeitos adversos
Medicamentos Biossimilares/química
Serviços Comunitários de Farmácia
Composição de Medicamentos
Terapia de Reposição de Estrogênios/efeitos adversos
Estrogênios Conjugados (USP)/efeitos adversos
Estrogênios Conjugados (USP)/química
Feminino
Seres Humanos
Meia-Idade
Congêneres da Progesterona/efeitos adversos
Congêneres da Progesterona/química
Estudos Retrospectivos
Inquéritos e Questionários
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biosimilar Pharmaceuticals); 0 (Estrogens, Conjugated (USP)); 0 (Progesterone Congeners)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170605
[Lr] Data última revisão:
170605
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170328
[St] Status:MEDLINE


  3 / 3092 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28214940
[Au] Autor:Shi WJ; Ying GG; Huang GY; Liang YQ; Hu LX; Zhao JL; Zhang JN
[Ad] Endereço:State Key Laboratory of Organic Geochemistry, CAS Research Centre of PRD Environmental Pollution and Control, Guangzhou Institute of Geochemistry, Chinese Academy of Sciences, 510640, Guangzhou, China.
[Ti] Título:Transcriptional and Biochemical Alterations in Zebrafish Eleuthero-Embryos (Danio rerio) After Exposure to Synthetic Progestogen Dydrogesterone.
[So] Source:Bull Environ Contam Toxicol;99(1):39-45, 2017 Jul.
[Is] ISSN:1432-0800
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Little information has so far been known on the effects of synthetic progestogen dydrogesterone (DDG) in organisms like fish. This study aimed to investigate the effects of DDG on the transcriptional and biochemical alterations in zebrafish eleuthero-embryos. Zebrafish eleuthero-embryos were analyzed for the transcriptional alterations by real-time quantitative PCR (RT-qPCR) and biochemical changes by attenuated total reflection Fourier-transform infrared spectroscopy (ATR-FITR) after 144 h exposure to DDG. The results of qPCR analysis showed that DDG exposure significantly suppressed the transcriptions of target genes involved in hypothalamic-pituitary-thyroid (HPT) axis, while it induced the expression of target genes mRNA belonging to hypothalamic-pituitary-gonad (HPG) axis. In addition, ATR-FTIR spectroscopy analysis showed that the biochemical alterations of protein, nucleic acid and lipid were observed following DDG treatment. The finding from this study suggests that DDG exposure could have potential multiple effects in fish.
[Mh] Termos MeSH primário: Didrogesterona/toxicidade
Embrião não Mamífero/efeitos dos fármacos
Disruptores Endócrinos/toxicidade
Poluentes Químicos da Água/toxicidade
Peixe-Zebra/embriologia
[Mh] Termos MeSH secundário: Animais
Eleutherococcus
Sistema Endócrino
Congêneres da Progesterona
Poluentes Químicos da Água/metabolismo
Peixe-Zebra/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Endocrine Disruptors); 0 (Progesterone Congeners); 0 (Water Pollutants, Chemical); 90I02KLE8K (Dydrogesterone)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170718
[Lr] Data última revisão:
170718
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170220
[St] Status:MEDLINE
[do] DOI:10.1007/s00128-017-2046-1


  4 / 3092 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28339382
[Au] Autor:Deleruyelle LJ
[Ad] Endereço:Frances Payne Bolton School of Nursing at Case Western Reserve University. dr.laura63@hotmail.com.
[Ti] Título:Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 2.
[So] Source:Int J Pharm Compd;20(6):447-454, 2016 Nov-Dec.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The use of compounded bioidentical hormone replacement therapy by menopausal women has become a popular alternative to traditional synthetic conjugated equine estrogen and progestin hormone replacement therapy due to safety concerns raised by recent studies. However, due to the lack of randomized, large-scale trials to evaluate the efficacy and side-effect profile of compounded bioidentical hormone replacement therapy many healthcare providers are reluctant to prescribe such therapy. The purpose of this study was to compare women's menopausal symptom relief and side effects experienced when using compounded bioidentical hormone replacement therapy and traditional hormone replacement therapy. A descriptive comparative design was used. Inferential and descriptive statistical procedures including a paired difference t-test, two-sample t-test, and f-tests (percentage, mean, standard deviation, frequency) were run on the Statistical Package for the Social Sciences. The framework used to guide this study was Lenz and Pugh's Theory of Unpleasant Symptoms. Surveys were distributed once to a convenient sample of women aged 35 and older when they dropped off or picked up their prescriptions at a pharmacy. Of the 216 surveys distributed, 70 were returned from those women taking compounded bioidentical hormone replacement therapy and 53 from traditional hormone replacement therapy. The survey contained 15 questions pertaining to age, duration of hormone replacement therapy, type and formulation of hormone replacement therapy, reasons for initiating hormone replacement therapy, symptoms before and one month after hormone replacement therapy, and side effects related to hormone replacement therapy. Included in part 1 of this series of articles was the introduction to the study conducted and the results of the literature review that was conducted for the purpose of examining the current data related to the topic of hormone replacement therapy. Part 2 provides a brief discussion on the significance of this study to nursing and provides the methods used in this study. The results of this study will be summarized in forthcoming articles in this series.
[Mh] Termos MeSH primário: Medicamentos Biossimilares/administração & dosagem
Terapia de Reposição de Estrogênios/métodos
Estrogênios Conjugados (USP)/administração & dosagem
Menopausa/efeitos dos fármacos
Congêneres da Progesterona/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Medicamentos Biossimilares/efeitos adversos
Medicamentos Biossimilares/química
Formas de Dosagem
Composição de Medicamentos
Terapia de Reposição de Estrogênios/efeitos adversos
Estrogênios Conjugados (USP)/efeitos adversos
Estrogênios Conjugados (USP)/química
Feminino
Seres Humanos
Assistência Farmacêutica
Congêneres da Progesterona/efeitos adversos
Congêneres da Progesterona/química
Estudos Retrospectivos
Inquéritos e Questionários
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biosimilar Pharmaceuticals); 0 (Dosage Forms); 0 (Estrogens, Conjugated (USP)); 0 (Progesterone Congeners)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170605
[Lr] Data última revisão:
170605
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170325
[St] Status:MEDLINE


  5 / 3092 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27810035
[Au] Autor:McCue PM
[Ad] Endereço:Equine Reproduction Laboratory, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, 3101 Rampart Road, Ft. Collins, CO 80523, USA. Electronic address: pmccue@colostate.edu.
[Ti] Título:Hormone Therapy in Clinical Equine Practice.
[So] Source:Vet Clin North Am Equine Pract;32(3):425-434, 2016 Dec.
[Is] ISSN:1558-4224
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A wide variety of hormone therapies are used in clinical practice in the reproductive management of horses. The goal of this article is to review therapeutic options for a variety of clinical indications.
[Mh] Termos MeSH primário: Criação de Animais Domésticos
Hormônios Esteroides Gonadais/administração & dosagem
Cavalos/fisiologia
[Mh] Termos MeSH secundário: Animais
Sincronização do Estro
Feminino
Lactação
Masculino
Gravidez
Congêneres da Progesterona/administração & dosagem
Acetato de Trembolona/administração & dosagem
Acetato de Trembolona/análogos & derivados
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Gonadal Steroid Hormones); 0 (Progesterone Congeners); 2U0X0JA2NB (altrenogest); RUD5Y4SV0S (Trenbolone Acetate)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161105
[St] Status:MEDLINE


  6 / 3092 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27349885
[Au] Autor:McConaghy FF; Green LA; Colgan S; Morris LH
[Ad] Endereço:Ceva Animal Health Pty Ltd, 11 Moores Rd, Glenorie, New South Wales 2157, Australia. finola.mcconaghy@ceva.com.
[Ti] Título:Studies of the pharmacokinetic profile, in vivo efficacy and safety of injectable altrenogest for the suppression of oestrus in mares.
[So] Source:Aust Vet J;94(7):248-55, 2016 Jul.
[Is] ISSN:1751-0813
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To investigate the efficacy and safety of the long-acting altrenogest injection (NV Readyserve® injection) for horses. DESIGN: A single-dose pharmacokinetic (PK) study was conducted. The in vivo efficacy study was a blinded, repeated measures design evaluating behaviour scores. The safety study was a non-blinded, controlled, parallel-group, randomised-block design as per the VICH protocol. METHODS: In the PK study, serial blood samples were obtained for analysis of plasma altrenogest for 150 h following the injection and a non-compartmental PK analysis was performed. For the efficacy study, 12 mares in oestrus were treated; they were monitored daily for 10 days for signs of oestrus during teasing and given a behaviour score that was compared with pretreatment scores. A standard safety study was conducted at 1-, 3- and 5-fold the recommended dosage for 84 days. Physical, haematological and biochemical examinations were performed. RESULTS: Mean plasma altrenogest concentrations were greater than ≈0.5 ng/mL for 148 h following administration. Oestrous behaviour was suppressed in all mares within 24 h of administration. Two mares returned to oestrus by day 6 and the rest on days 7-10. In the safety study there were no significant differences in the physical and haematological examinations, but minor biochemical changes in muscle enzymes. There was a low incidence of injection site reactions following the 3- and 5-fold dose, predominantly for pectoral injections. CONCLUSION: These studies support the efficacy and safety of a single dose of Readyserve® injection for the suppression of the signs of oestrus in mares for 5-7 days.
[Mh] Termos MeSH primário: Estro/efeitos dos fármacos
Cavalos/fisiologia
Congêneres da Progesterona/farmacocinética
Acetato de Trembolona/análogos & derivados
[Mh] Termos MeSH secundário: Animais
Feminino
Injeções Intramusculares/veterinária
Progesterona/sangue
Congêneres da Progesterona/efeitos adversos
Congêneres da Progesterona/farmacologia
Acetato de Trembolona/efeitos adversos
Acetato de Trembolona/farmacocinética
Acetato de Trembolona/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Progesterone Congeners); 2U0X0JA2NB (altrenogest); 4G7DS2Q64Y (Progesterone); RUD5Y4SV0S (Trenbolone Acetate)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170130
[Lr] Data última revisão:
170130
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160629
[St] Status:MEDLINE
[do] DOI:10.1111/avj.12459


  7 / 3092 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27245768
[Au] Autor:Cano-Nicolau J; Garoche C; Hinfray N; Pellegrini E; Boujrad N; Pakdel F; Kah O; Brion F
[Ad] Endereço:Team NEED, Institut de recherche en Santé Environnement et Travail (Irset), INSERM U1085, Université de Rennes 1, Campus de Beaulieu, SFR Biosit, 35042 Rennes cedex, France.
[Ti] Título:Several synthetic progestins disrupt the glial cell specific-brain aromatase expression in developing zebra fish.
[So] Source:Toxicol Appl Pharmacol;305:12-21, 2016 Aug 15.
[Is] ISSN:1096-0333
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The effects of some progestins on fish reproduction have been recently reported revealing the hazard of this class of steroidal pharmaceuticals. However, their effects at the central nervous system level have been poorly studied until now. Notwithstanding, progesterone, although still widely considered primarily a sex hormone, is an important agent affecting many central nervous system functions. Herein, we investigated the effects of a large set of synthetic ligands of the nuclear progesterone receptor on the glial-specific expression of the zebrafish brain aromatase (cyp19a1b) using zebrafish mechanism-based assays. Progesterone and 24 progestins were first screened on transgenic cyp19a1b-GFP zebrafish embryos. We showed that progesterone, dydrogesterone, drospirenone and all the progesterone-derived progestins had no effect on GFP expression. Conversely, all progestins derived from 19-nortesterone induced GFP in a concentration-dependent manner with EC50 ranging from the low nM range to hundreds nM. The 19-nortestosterone derived progestins levonorgestrel (LNG) and norethindrone (NET) were further tested in a radial glial cell context using U251-MG cells co-transfected with zebrafish ER subtypes (zfERα, zfERß1 or zfERß2) and cyp19a1b promoter linked to luciferase. Progesterone had no effect on luciferase activity while NET and LNG induced luciferase activity that was blocked by ICI 182,780. Zebrafish-ERs competition assays showed that NET and LNG were unable to bind to ERs, suggesting that the effects of these compounds on cyp19a1b require metabolic activation prior to elicit estrogenic activity. Overall, we demonstrate that 19-nortestosterone derived progestins elicit estrogenic activity by inducing cyp19a1b expression in radial glial cells. Given the crucial role of radial glial cells and neuro-estrogens in early development of brain, the consequences of exposure of fish to these compounds require further investigation.
[Mh] Termos MeSH primário: Aromatase/metabolismo
Neuroglia/efeitos dos fármacos
Congêneres da Progesterona/farmacologia
Proteínas de Peixe-Zebra/metabolismo
[Mh] Termos MeSH secundário: Androgênios/farmacologia
Animais
Animais Geneticamente Modificados
Aromatase/genética
Encéfalo/efeitos dos fármacos
Encéfalo/metabolismo
Linhagem Celular Tumoral
Estradiol/farmacologia
Estrogênios/farmacologia
Proteínas de Fluorescência Verde/genética
Proteínas de Fluorescência Verde/metabolismo
Seres Humanos
Neuroglia/metabolismo
Receptores Estrogênicos/metabolismo
Testosterona/farmacologia
Peixe-Zebra
Proteínas de Peixe-Zebra/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgens); 0 (Estrogens); 0 (Progesterone Congeners); 0 (Receptors, Estrogen); 0 (Zebrafish Proteins); 147336-22-9 (Green Fluorescent Proteins); 3XMK78S47O (Testosterone); 4TI98Z838E (Estradiol); EC 1.14.14.1 (Aromatase)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160602
[St] Status:MEDLINE


  8 / 3092 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26909949
[Au] Autor:Le AW; Shan LL; Dai XY; Xiao TH; Li XR; Wang ZH; Zhang J; Chen XY
[Ad] Endereço:Department of Obstetrics and Gynecology, Affiliated Shenzhen Nanshan People's Hospital of Guangdong Medical University, Shenzhen, China.
[Ti] Título:PI3K, AKT, and P-AKT levels in thin endometrium.
[So] Source:Genet Mol Res;15(1), 2016 Feb 05.
[Is] ISSN:1676-5680
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to explore the expression of PI3K, AKT, and P-AKT, and to investigate the role of PI3K/AKT signaling pathway in thin endometrium. We included 40 women treated in affiliated Shenzhen Nanshan People's Hospital of Guangdong Medical University for endometrial conditions between August 2013 and January 2015, 20 with a normal endometrium, and 20 with thin endometrium. The expression of PI3K, AKT, and P-AKT was evaluated by the immunohistochemical S-P method. The expression of PI3K, AKT, and P-AKT proteins was significantly lower in the thin endometrium group than in the normal endometrium group (P < 0.05). The expression of PI3K and AKT was positively correlated with the expression of P-AKT. The expression of PI3K, AKT, and P-AKT proteins in the thin endometrium decreases during the proliferative phase, and this process could be associated with PI3K/AKT signaling.
[Mh] Termos MeSH primário: Endométrio/metabolismo
Fosfatidilinositol 3-Quinases/genética
Fosfoproteínas/genética
Proteínas Proto-Oncogênicas c-akt/genética
[Mh] Termos MeSH secundário: Adulto
Estudos de Casos e Controles
Endométrio/patologia
Congêneres do Estradiol/sangue
Feminino
Regulação da Expressão Gênica
Seres Humanos
Fosfatidilinositol 3-Quinases/sangue
Fosfoproteínas/sangue
Congêneres da Progesterona/sangue
Proteínas Proto-Oncogênicas c-akt/sangue
Transdução de Sinais
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Estradiol Congeners); 0 (Phosphoproteins); 0 (Progesterone Congeners); EC 2.7.1.- (Phosphatidylinositol 3-Kinases); EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
[Em] Mês de entrada:1611
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160225
[St] Status:MEDLINE
[do] DOI:10.4238/gmr.15017184


  9 / 3092 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26627933
[Au] Autor:Manes J; Ríos G; Fiorentino MA; Ungerfeld R
[Ad] Endereço:Biotecnología de la Reproducción, Departamento de Producción Animal, Estación Experimental Agropecuaria Balcarce, Instituto Nacional de Tecnología Agropecuaria, Balcarce, Argentina; Departamento de Fisiología, Facultad de Veterinaria, Universidad de la República, Montevideo, Uruguay.
[Ti] Título:Vaginal mucus from ewes treated with progestogen sponges affects quality of ram spermatozoa.
[So] Source:Theriogenology;85(5):856-861, 2016 Mar 15.
[Is] ISSN:1879-3231
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The use of intravaginal sponges (IS) to synchronize estrous onset in ewes provokes vaginitis, an increase in the vaginal bacterial load, and growth of bacterial species that are not present during spontaneous estrous behavior. The objective of the study was to compare the functional sperm parameters after incubating it with mucus collected from the vagina of ewes during spontaneous estrus or estrous synchronized with IS. Pooled spermatozoa were co-incubated with: (1) vaginal mucus collected from ewes in spontaneous estrus; (2) vaginal mucus collected from ewes in estrus pretreated with progestogen-impregnated IS; (3) synthetic mucus; and (4) medium without mucus as a control group. Sperm samples were evaluated after incubating it for 30 and 90 minutes. The number of colony-forming units (CFUs/mL), pH, and osmolality were greater in the mucus collected from ewes treated with IS than from those untreated (P = 0.046; P < 0.0001, and P < 0.0001, respectively). The percentage of sperm with progressive motility was lower after incubation with vaginal mucus collected from estrous ewes treated with IS than in the other three treatments both, 30 and 90 minutes after incubation (P = 0.0009 and P < 0.0001, respectively). The sample incubated for 30 minutes with mucus from ewes treated with IS had a lower percentage of sperm with intact plasma membrane than all the other treatments (P < 0.0001). The percentage of sperm with functional membrane was significantly lower in the sample incubated for 30 minutes with vaginal mucus from ewes treated with IS than in the other three treatments (P < 0.0001). After 90 minutes, the percentage was still lower than that in the sample collected from ewes during their spontaneous estrus (P = 0.0005). The lowest percentages of sperm with acrosome damage were observed in sperm incubated with mucus collected from sheep in spontaneous estrus for 30 and 90 minutes (P < 0.0001 and P = 0.008, respectively). The percentage of apoptotic spermatozoa was greater in samples incubated during 30 minutes with vaginal mucus collected from ewes treated with IS than in the other three groups (P = 0.0005). The functionality and the viability of ram sperm is negatively affected by the cervical mucus of ewes pretreated with progestagen-impregnated IS used in estrous synchronization treatments. This may partially explain the decrease in conception rate obtained with treatments with IS.
[Mh] Termos MeSH primário: Muco do Colo Uterino/efeitos dos fármacos
Dispositivos Anticoncepcionais Femininos
Congêneres da Progesterona/administração & dosagem
Análise do Sêmen
Ovinos
Espermatozoides/efeitos dos fármacos
[Mh] Termos MeSH secundário: Administração Intravaginal
Animais
Muco do Colo Uterino/química
Muco do Colo Uterino/fisiologia
Dispositivos Anticoncepcionais Femininos/veterinária
Sincronização do Estro/métodos
Feminino
Concentração de Íons de Hidrogênio
Masculino
Concentração Osmolar
Gravidez
Congêneres da Progesterona/farmacologia
Análise do Sêmen/veterinária
Espermatozoides/citologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Progesterone Congeners)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:170728
[Lr] Data última revisão:
170728
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151203
[St] Status:MEDLINE


  10 / 3092 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26463434
[Au] Autor:Chandra V; Kim JJ; Benbrook DM; Dwivedi A; Rai R
[Ad] Endereço:Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
[Ti] Título:Therapeutic options for management of endometrial hyperplasia.
[So] Source:J Gynecol Oncol;27(1):e8, 2016 Jan.
[Is] ISSN:2005-0399
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:Endometrial hyperplasia (EH) comprises a spectrum of changes in the endometrium ranging from a slightly disordered pattern that exaggerates the alterations seen in the late proliferative phase of the menstrual cycle to irregular, hyperchromatic lesions that are similar to endometrioid adenocarcinoma. Generally, EH is caused by continuous exposure of estrogen unopposed by progesterone, polycystic ovary syndrome, tamoxifen, or hormone replacement therapy. Since it can progress, or often occur coincidentally with endometrial carcinoma, EH is of clinical importance, and the reversion of hyperplasia to normal endometrium represents the key conservative treatment for prevention of the development of adenocarcinoma. Presently, cyclic progestin or hysterectomy constitutes the major treatment option for EH without or with atypia, respectively. However, clinical trials of hormonal therapies and definitive standard treatments remain to be established for the management of EH. Moreover, therapeutic options for EH patients who wish to preserve fertility are challenging and require nonsurgical management. Therefore, future studies should focus on evaluation of new treatment strategies and novel compounds that could simultaneously target pathways involved in the pathogenesis of estradiol-induced EH. Novel therapeutic agents precisely targeting the inhibition of estrogen receptor, growth factor receptors, and signal transduction pathways are likely to constitute an optimal approach for treatment of EH.
[Mh] Termos MeSH primário: Hiperplasia Endometrial/terapia
[Mh] Termos MeSH secundário: Antineoplásicos Hormonais/efeitos adversos
Gerenciamento Clínico
Progressão da Doença
Hiperplasia Endometrial/classificação
Hiperplasia Endometrial/etiologia
Feminino
Hormônio Liberador de Gonadotropina/uso terapêutico
Seres Humanos
Histerectomia
Terapia de Alvo Molecular/métodos
Congêneres da Progesterona/uso terapêutico
Fatores de Risco
Tamoxifeno/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents, Hormonal); 0 (Progesterone Congeners); 094ZI81Y45 (Tamoxifen); 33515-09-2 (Gonadotropin-Releasing Hormone)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151015
[St] Status:MEDLINE
[do] DOI:10.3802/jgo.2016.27.e8



página 1 de 310 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde